Sepsis triggers multiple parallel inflammatory signaling pathways. Of these pathways, which ones contribute most substantially to adverse outcomes and, therefore, are relevant targets for new therapies? N100 clinical trials of mediator modulators in sepsis patients have failed (Marshall, 2014) suggesting that we need new information to direct our search. In other disease states a genome-wide association study design is an unbiased approach that has identified genes in key pathways (Altshuler et al., 2008) . For example, PCSK9 was discovered using genetic association analysis of patients who had LDL levels measured (Abifadel et al., 2003) . This has led to the introduction of PCSK9 inhibitors as a treatment for hypercholesterolemia where other treatments have failed. Can a similar genetic association strategy work in the complex milieu of sepsis?
In the current issue of EBioMedicine, (2016-in this issue) conducted a genome-wide association study for 28-day mortality, initially in 740 septic patients. The authors followed standard quality control practices to limit any potential methodological errors in their discovery GWAS. From 644,699 SNPs they imputed 7,993,459 SNPs for their GWAS analysis.
These investigators found that a missense genetic variant located within the VPS13A gene was associated with 28-day mortality in sepsis. This was the strongest association observed within the primary GWAS analysis (p = 8.2 × 10
−8
). The minor allele, associated with adverse outcome, occurred only 1% of the time so this association is very susceptible to a false positive result since only a small number of patients would carry this adverse genetic variant -the conclusions are based on a few "affected" patients. Therefore, replication of this finding was essential. These investigators took the relatively rare (within the critical care community), but crucial, step of reaching out to previous investigators with large genotyped sepsis cohorts. This VPS13A finding replicated to a reasonable extent (associated with SOFA severity of illness score) in a second large cohort of patients from the PROGRESS study (ClinicalTrials.gov: NCT02782013). Finally, taking all genetic variants found by sequencing across the VPS13A gene, the VPS13A gene was also found to be associated with 28-day mortality. A bioinformatics in silico analysis suggests that this protein-altering SNP (rs117983287) is predicted to be highly deleterious to VPS13A function. The original finding plus replication and further support from the sequencing study and in silico analysis leads to the potentially important and exciting finding that a signaling pathway involving VPS13A is associated with sepsis outcome. Not much is known about VPS13A function as it relates to sepsis (Munoz-Braceras et al., 2015) so much work remains. Indeed, there are many other genes in this region so it is not yet certain that VPS13A causally impacts sepsis outcome.
The authors identified 13 other genetic variants that are promising candidates. None of these additional genetic variants reached the prespecified level of statistical significance and therefore do not meet the discovery threshold but remain as promising candidates requiring further work and validation. When tested for replication in the collaborators' genotyped sepsis cohorts, none replicated to the same extent as VPS13A. Among this set, the best candidates included CRISPLD2 (p = 5.99 × 10
) and a region on chromosome 13q21.33 (p = 3.34 × 10
−7
). Reversing the replication strategy, these investigators tested for replication of top association findings previously reported by Rautanen et al. (Rautanen et al., 2015) . They did not observe directionally similar significant findings for any of the reported SNPs. Again, it must be appreciated that for genetic association studies, the currently reported cohort is quite small and therefore does not have much statistical power to find true associations.
The use of previous data to "look-up" potential new discoveries is a very encouraging event. First, replication of the key result is impressive validation and greatly increases the probability that the primary discovery is biologically real and not a statistical fluke. Second, sharing of data is an exciting trend that will certainly improve the veracity of reported results. Another encouraging step was the use of gene-based analysis for replication. Single SNP associations may not identify causal SNPs and may simply be markers in linkage disequilibrium with the underlying causal genetic variants. Sequencing all SNPs within the identified gene is a more powerful approach (Lee et al., 2012) . The increased 
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EBioMedicine j o u r n a l h o m e p a g e : w w w . e b i o m e d i c i n e . c o m statistical power of this approach (Taudien et al., 2016) is tempered by the smaller number of patients within this substudy in the current report. Nevertheless, replication of gene association greatly reduces that chance that a SNP association is a false positive result. The current report highlights bad and good features of genetic association studies in sepsis, ARDS, and critical illness. A key bad feature is the relatively low power we currently have to make discoveries because we have not put together sufficiently large genotyped sepsis cohorts. Cohorts in the tens of thousands have successfully identified key genes in, for example, atherosclerosis and asthma. This has led to the development of highly successful new drugs. The very good feature of the current report is that these investigators, and indeed the critical care community, are now starting to coalesce in order to address the important observations arising from genetic association studies. Let's put together the first N 10,000 patient genetic association study in sepsis and start to make the really exciting discoveries that will transform patient care and outcomes.
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